World Orphan Drug Congress EU 2020
Featured Presentations
Use of Novel AI/ML Tools to Support Patient Identification; Perspectives From the Syneos Health Rare Disease Consortium
Monday, November 2nd | 10 – 13:00 CET
Co-hosted by:
- Ray Huml, Vice President, Medical & Scientific Strategy, Rare Diseases Consortium
Making a Successful Transition from Orphan Drug Designation to Orphan Drug Exclusivity
Tuesday, November 3rd | 11:30 CET
Presented by:
- Zohra Lomri, Senior Director, Regulatory Consulting
Accelerating Rare Disease Drug Development in the COVID-19 Era and beyond.
Tuesday, November 3rd | 15:45 CET
Presented by:
- Zizi Imatorbhebhe , MS MBA Vice President, Global Clinical Drug Development, Rare Diseases
- Cinzia Dorigo, PharmD Vice President, Global Clinical Drug Development, Rare Diseases
New Models to Run Natural History Studies & Registries: Perspectives From Patients, Industry, CROs & Regulators on Sustainable RWE
Tuesday, November 3rd | 17:45 CET
Presented by:
- Javier Jimenez, Executive Vice President, RWE & Late Phase
- Ray Huml, Vice President, Medical & Scientific Strategy & Head, Rare Disease Consortium
An Integrated Development Plan in Rare & Orphan Medicinal Products (OMPs): Significantly Accelerating Time-to-Approval and Strengthening Asset Value for All Key Industry Stakeholders
Thursday, November 5th | 9:40 CET
Presented by:
- Maryna Kolochavina, PharmD, PMP, Executive Director, Syneos One
